Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV).

Clifford A. Hudis, Kurt W. Tauer, Robert C. Hermann, Grace Makari‐Judson, Claudine Isaacs, J. Thaddeus Beck, Virginia Kaklamani, Edward J. Stepanski, H. S. Rugo, W. Wang,

Journal of Clinical Oncology · 2011 · 24 citations · 0 references

Concepts

Abstract

1009